Myopericarditis following both BNT162b2 and NVX-CoV2373.
BNT162b2
COVID-19
Myocarditis
Myopericarditis
NVX-CoV2373
Pericarditis
SARS-Cov-2
Vaccination
mRNA-1273
Journal
Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology
ISSN: 1710-1484
Titre abrégé: Allergy Asthma Clin Immunol
Pays: England
ID NLM: 101244313
Informations de publication
Date de publication:
23 Dec 2022
23 Dec 2022
Historique:
received:
16
10
2022
accepted:
08
12
2022
entrez:
23
12
2022
pubmed:
24
12
2022
medline:
24
12
2022
Statut:
epublish
Résumé
Myopericarditis is a well reported complication associated with SARS-Cov-2 (COVID-19) infection and vaccinations; particularly with mRNA vaccines (BNT162b2 and mRNA-1273), and in the young male population. The risk-to-benefit ratio in sequential vaccination dosing in young males is further clouded in the era of the omicron variant with its reported enhanced immune escape. A case series of two cases of post vaccination myopericarditis following the NVX-CoV2373 after also developing myopericarditis with BNT162b2. To our knowledge, we are the first to describe post vaccination myopericarditis following NVX-CoV2373 after also developing myopericarditis with BNT162b2. The similarities in presentation between the reactions of both platforms would suggest a similar pathogenesis, although the exact mechanism remains unknown. Further studies are necessary to identify these mechanisms, as well as to identify biomarkers that may identify vulnerable populations. On-going vigilance is necessary to identify those who may be at an increased risk of post-COVID vaccine myopericarditis.
Sections du résumé
BACKGROUND
BACKGROUND
Myopericarditis is a well reported complication associated with SARS-Cov-2 (COVID-19) infection and vaccinations; particularly with mRNA vaccines (BNT162b2 and mRNA-1273), and in the young male population. The risk-to-benefit ratio in sequential vaccination dosing in young males is further clouded in the era of the omicron variant with its reported enhanced immune escape.
STUDY DESIGN
METHODS
A case series of two cases of post vaccination myopericarditis following the NVX-CoV2373 after also developing myopericarditis with BNT162b2.
CONCLUSION
CONCLUSIONS
To our knowledge, we are the first to describe post vaccination myopericarditis following NVX-CoV2373 after also developing myopericarditis with BNT162b2. The similarities in presentation between the reactions of both platforms would suggest a similar pathogenesis, although the exact mechanism remains unknown. Further studies are necessary to identify these mechanisms, as well as to identify biomarkers that may identify vulnerable populations. On-going vigilance is necessary to identify those who may be at an increased risk of post-COVID vaccine myopericarditis.
Identifiants
pubmed: 36564782
doi: 10.1186/s13223-022-00750-7
pii: 10.1186/s13223-022-00750-7
pmc: PMC9786414
doi:
Types de publication
Journal Article
Langues
eng
Pagination
109Informations de copyright
© 2022. Crown.
Références
Nat Med. 2022 Feb;28(2):410-422
pubmed: 34907393
Vaccine. 2022 Mar 1;40(10):1499-1511
pubmed: 35105494
Circulation. 2021 Aug 10;144(6):506-508
pubmed: 34133884
Heart Rhythm. 2020 Sep;17(9):1463-1471
pubmed: 32387246
Nat Commun. 2022 Jun 25;13(1):3633
pubmed: 35752614
MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):132-138
pubmed: 35085223
Nat Rev Cardiol. 2022 Feb;19(2):75-77
pubmed: 34887571
Metabol Open. 2022 Mar;13:100159
pubmed: 34938983
J Am Coll Cardiol. 2004 May 5;43(9):1503-10
pubmed: 15120802